381 related articles for article (PubMed ID: 26804029)
1. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
Arcuri L; Viaro R; Bido S; Longo F; Calcagno M; Fernagut PO; Zaveri NT; Calò G; Bezard E; Morari M
Neurobiol Dis; 2016 May; 89():55-64. PubMed ID: 26804029
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.
Mabrouk OS; Viaro R; Volta M; Ledonne A; Mercuri N; Morari M
J Neurosci; 2014 Sep; 34(39):12953-62. PubMed ID: 25253844
[TBL] [Abstract][Full Text] [Related]
3. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity.
Volta M; Viaro R; Trapella C; Marti M; Morari M
Exp Neurol; 2011 Mar; 228(1):126-37. PubMed ID: 21215744
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies.
Rizzi A; Gavioli EC; Marzola G; Spagnolo B; Zucchini S; Ciccocioppo R; Trapella C; Regoli D; Calò G
J Pharmacol Exp Ther; 2007 Jun; 321(3):968-74. PubMed ID: 17329551
[TBL] [Abstract][Full Text] [Related]
5. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
Mabrouk OS; Marti M; Morari M
Neuroscience; 2010 Mar; 166(1):40-8. PubMed ID: 20006677
[TBL] [Abstract][Full Text] [Related]
6. MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons.
Gouty S; Brown JM; Rosenberger J; Cox BM
Neuroscience; 2010 Aug; 169(1):269-78. PubMed ID: 20417255
[TBL] [Abstract][Full Text] [Related]
7. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
Spagnolo B; Carrà G; Fantin M; Fischetti C; Hebbes C; McDonald J; Barnes TA; Rizzi A; Trapella C; Fanton G; Morari M; Lambert DG; Regoli D; Calò G
J Pharmacol Exp Ther; 2007 Jun; 321(3):961-7. PubMed ID: 17329552
[TBL] [Abstract][Full Text] [Related]
9. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.
Marti M; Mela F; Veronesi C; Guerrini R; Salvadori S; Federici M; Mercuri NB; Rizzi A; Franchi G; Beani L; Bianchi C; Morari M
J Neurosci; 2004 Jul; 24(30):6659-66. PubMed ID: 15282268
[TBL] [Abstract][Full Text] [Related]
10. Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.
Marti M; Mela F; Budri M; Volta M; Malfacini D; Molinari S; Zaveri NT; Ronzoni S; Petrillo P; Calò G; Morari M
Br J Pharmacol; 2013 Feb; 168(4):863-79. PubMed ID: 22994368
[TBL] [Abstract][Full Text] [Related]
11. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism.
Viaro R; Sanchez-Pernaute R; Marti M; Trapella C; Isacson O; Morari M
Neurobiol Dis; 2008 Jun; 30(3):430-438. PubMed ID: 18413287
[TBL] [Abstract][Full Text] [Related]
12. Quantitative study of the antagonistic effect of (-)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111) on nociceptin/orphanin FQ-mediated potassium channel activation in rat periaqueductal gray slices.
Liao YY; Jiang F; Chiou LC
Eur J Pharmacol; 2011 Apr; 657(1-3):84-8. PubMed ID: 21300055
[TBL] [Abstract][Full Text] [Related]
13. Managing Parkinson's disease: moving ON with NOP.
Mercatelli D; Bezard E; Eleopra R; Zaveri NT; Morari M
Br J Pharmacol; 2020 Jan; 177(1):28-47. PubMed ID: 31648371
[TBL] [Abstract][Full Text] [Related]
14. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.
Marti M; Mela F; Fantin M; Zucchini S; Brown JM; Witta J; Di Benedetto M; Buzas B; Reinscheid RK; Salvadori S; Guerrini R; Romualdi P; Candeletti S; Simonato M; Cox BM; Morari M
J Neurosci; 2005 Oct; 25(42):9591-601. PubMed ID: 16237164
[TBL] [Abstract][Full Text] [Related]
15. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
16. NOP Receptor Ligands and Parkinson's Disease.
Mercatelli D; Pisanò CA; Novello S; Morari M
Handb Exp Pharmacol; 2019; 254():213-232. PubMed ID: 30689087
[TBL] [Abstract][Full Text] [Related]
17. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Marti M; Trapella C; Morari M
J Neurochem; 2008 Dec; 107(6):1683-96. PubMed ID: 19014386
[TBL] [Abstract][Full Text] [Related]
18. Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats.
Di Benedetto M; Cavina C; D'Addario C; Leoni G; Candeletti S; Cox BM; Romualdi P
Neuropharmacology; 2009 Mar; 56(4):761-7. PubMed ID: 19162046
[TBL] [Abstract][Full Text] [Related]
19. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice.
Khroyan TV; Polgar WE; Orduna J; Montenegro J; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2011 Nov; 339(2):687-93. PubMed ID: 21859931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
